Results were presented in August 2026 at the European Society of Cardiology meeting. See press release at
ENRICH-AF stands for EdoxabaN for IntraCranial Haemorrhage survivors with Atrial Fibrillation.
Bleeding within the skull, also known as brain haemorrhage, affects 3 million people in the world each year.
One in five people who survive brain haemorrhage have an irregular heart rhythm called 'atrial fibrillation', which puts them at risk of stroke and other blood clots.
Blood-thinning medicines, known as 'anticoagulant' drugs, are used in everyday clinical practice to protect people with atrial fibrillation from developing blood clots. However, as these drugs also increase the risk of bleeding, it is not known whether they should be prescribed to people who have had a brain haemorrhage.
ENRICH-AF is a randomised clinical trial to produce reliable information about whether people with atrial fibrillation who have had a brain haemorrhage benefit from starting anticoagulant drugs.
More information
Population Health Research Institute
ClinicalTrials.gov identifier: NCT03950076
